Laser-assisted blood assay detects colorectal cancer biomarker within minutes
Researchers at Osaka Metropolitan University used laser irradiation to accelerate binding between antibody-coated microscopic beads and CEACAM-5, a biomarker associated with colorectal cancer. In diluted blood plasma, the method detected CEACAM-5 at 1–10 picograms per milliliter within minutes. The work is an early laboratory result; clinical validation is still needed.
The story
A research team at Osaka Metropolitan University reported a light-assisted method for detecting CEACAM-5, a glycoprotein biomarker associated with colorectal cancer, in blood plasma. The system places antibody-coated microscopic beads in a small flow channel containing plasma. Laser irradiation then enhances interactions between the antibodies and CEACAM-5, prompting the beads to assemble into measurable clusters. The researchers call the approach the Light-induced Acceleration System, or LAC-SYS. In experiments using serially diluted plasma, the method detected CEACAM-5 at concentrations of 1–10 picograms per milliliter within a few minutes. Each experiment used 5 microliters of plasma, and the team mainly used samples diluted 1,000-fold from patients with colorectal cancer. The researchers reported that this detection range could be one to two orders of magnitude lower than conventional immunoassays such as enzyme-linked immunosorbent assays and immunoprecipitation. The study also found that CEACAM-5 appeared in blood as nanoscale aggregates. The researchers suggest these aggregates may interact efficiently with the antibody-coated beads and help produce the observed signal. The findings were published in Nanoscale Horizons.
Why it matters
Blood-based biomarker testing can be limited by the small amount of target material present and by lengthy incubation and washing stages. The reported assay is designed to address both constraints by making antibody-target interactions occur more quickly and by measuring bead assembly as the readout. That could be useful for liquid-biopsy research, where blood samples are used to look for disease-related signals without a tissue procedure. However, detecting one biomarker at low concentrations is not equivalent to diagnosing colorectal cancer: the assay will need testing in clinical settings to determine its reliability.
Evidence and context
Colorectal cancer is described in the source as the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths worldwide. Early detection is therefore a central aim of research into blood-based testing. Conventional immunoassays use antibodies to bind specific proteins, but can take hours because of incubation and washing steps; low-abundance targets in blood must also be distinguished among many other substances. The Osaka team’s approach retains antibody recognition while using laser irradiation and bead aggregation to create a detectable signal. Its observation that CEACAM-5 can occur as nanoscale aggregates is relevant to the proposed mechanism, although the source presents this as a possible explanation for the stronger signal rather than a confirmed clinical advantage.
Limits and unknowns
The result remains a laboratory-stage measurement, not a validated screening or diagnostic test. The reported detection experiments used diluted plasma, mainly 1,000-fold diluted samples from patients with colorectal cancer, so performance in routine clinical samples remains unresolved. The source does not establish clinical sensitivity, specificity, or how the test would perform against other conditions that may affect blood biomarkers. Researchers say their next task is clinical validation to determine how reliably the technology can distinguish disease-related signals, alongside work with industry partners on practical portable systems.
Follow the story
Share it, watch the explainer, or continue with the reporting trail.
Further reading on this topic
2 links
Royal Society of Chemistry
Primary research article cited in the report: “Light-induced acceleration of specific binding between CEACAM-5 and antibodies for early detection of colorectal cancer.”
Wikipedia
Background overview of colorectal cancer, including its diagnosis and disease context.
Laser-assisted blood assay detects colorectal cancer biomarker within minutes
A short visual explainer for readers who want the story in a different rhythm.
Highlights
- Early lab test detects a biomarker in minutes
- Laser light helps microscopic beads gather
- A measurable signal from 5 microliters
- Detected at 1–10 picograms per milliliter
Transcript
At Osaka Metropolitan University, an early lab assay detects a colorectal cancer biomarker within minutes.
Laser light in diluted plasma speeds binding between antibody-coated microscopic beads and the target protein.
The beads cluster, creating a measurable signal from five microliters of plasma per experiment.
It detected CEACAM-5 at one to ten picograms per milliliter, a tiny concentration.
Clinical validation is still needed, but this is a step toward faster, reliable blood-testing tools.